Early, Late Outcomes of Therapy for Diabetic Macular Edema Correlate
Early vision gains correlate with long-term visual outcomes in patients with diabetic macular edema (DME) treated with bevacizumab or dexamethasone implants, according to results from the BEVORDEX clinical trial, according to a Medscape report.
While resolution of DME, as measured by central macular thickness (CMT), is an important outcome of treatment, improvement in vision is a more important goal to patients.
Dr. Hemal Mehta from Sydney Medical School at the University of Sydney, Australia, and colleagues investigated whether visual outcomes at 12 weeks correlated with visual outcomes at two years after treatment, in their post hoc analysis of 68 eyes treated in the BEVORDEX randomized trial.
You must be logged in to leave a comment.